ERBB2 and breast carcinoma: Hormone receptor (HR)‐positive, human epidermal growth factor receptor 2 (HER2)‐negative tumors account for approximately two thirds of newly diagnosed breast cancer cases, some of which are effectively managed after surgical resection with endocrine therapy alone.1